Pete, great post and I mostly agree with you. The key point that you made is that Brilacidin is unique in that it kills the virus vs just slowing down the replication. This MOA is the key differentiator that will make Brilacidin rise to the top of all antivirals IMO.
I think the only person that knows with certainty at this time regarding Brilacidin CV19 efficacy is the CRO. The reason for this is because of the multiple trial site locations. If you are an individual site and have for example treated 10 patients (but do not know which 5 got Rem or Fav vs Brilacidin) you might see that 2 got better right away, 2 got better in 3 days, 2 got better in 5 days, 2 got better in 8 days and 2 were intubated with one of them making a full recovery. That site might not know with certainty that the best outcomes were due to B.
The CRO on the other hand has a much bigger picture currently with 70 plus patients (soon to be 120+) vs the 10 patients that the individual site sees. The CRO's job is to maintain the integrity of the trial until its completion and that includes not leaking data to ANYONE including IPIX, FDA or government agencies. IMO the CRO knows today that Brilacidin will save many lives and their job is to make sure the trial gets successfully completed so that it can indeed save those lives once the trial is completed.
The B-CV19 trial success at completion is the key milestone. IMO Leo has multiple avenues to proceed once the trial is completed which includes major funding, partnerships and revenue opportunities.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links